U.S. markets closed

ProQR Therapeutics N.V. (PRQR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.1300+0.1400 (+7.04%)
At close: 04:00PM EDT
2.0700 -0.06 (-2.82%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close1.9900
Bid2.1400 x 900
Ask2.1500 x 1800
Day's Range1.9400 - 2.2200
52 Week Range0.5300 - 3.8500
Avg. Volume1,281,972
Market Cap172.14M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.6500
Earnings DateMay 03, 2023 - May 08, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PRQR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ProQR Therapeutics N.V.
    QURE: Raising target price to $27.00UNIQURE NV has an Investment Rating of BUY; a target price of $27.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Motley Fool

    Why Shares of ProQR Therapeutics Dropped on Wednesday

    Shares of ProQR Therapeutics (NASDAQ: PRQR) were down 31% Wednesday morning after the company reported 2022 full-year earnings and updated the status of its pipeline. ProQR is a clinical-stage biopharmaceutical company that focuses on RNA-based therapies to treat rare genetic diseases, especially inherited eye diseases. ProQR released its fourth-quarter and full-year earnings before the market opened on Wednesday, along with an update regarding its pipeline.

  • GlobeNewswire

    ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

    Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025Axiomer activity demonstrated across multiple preclinical in vitro, organoid, and in vivo models; up to 50% editing observed in rodent and non-human primatesBeyond correction, broad applicability of Axiomer demonstrated in preclinical models with ability to modulate proteins by altering function

  • GlobeNewswire

    ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing

    LEIDEN, Netherlands & CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against two oppositions that were filed against a key patent for its ADAR-mediated RNA editing platform Axiomer®. The oppositions were filed in February 2021 with the European Patent Office (EPO) by two separate strawmen against ProQR’s granted patent EP 3